These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9349695)

  • 21. The next phase of chemoprevention research.
    Cohen EE; Schilsky RL
    Cancer Prev Res (Phila); 2011 Mar; 4(3):293-5. PubMed ID: 21372026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming Barriers to Clinical Trial Enrollment.
    Nipp RD; Hong K; Paskett ED
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():105-114. PubMed ID: 31099636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of human trial design.
    Buiatti E
    IARC Sci Publ; 1996; (139):261-9. PubMed ID: 8923036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical evaluation of cancer chemoprevention agents: defining and contrasting phase I, II, and III objectives.
    Goodman GE
    Cancer Res; 1992 May; 52(9 Suppl):2752s-2757s. PubMed ID: 1563007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoprevention of cancer: review of the literature.
    Swan DK; Ford B
    Oncol Nurs Forum; 1997 May; 24(4):719-27. PubMed ID: 9159786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Social factors affecting interest in participating in a prostate cancer chemoprevention trial.
    Lee MM; Chamberlain RM; Catchatourian R; Hiang J; Kopnick M; Ray P; Vijayakumar S
    J Cancer Educ; 1999; 14(2):88-92. PubMed ID: 10397483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of human trial findings.
    Huttunen JK
    IARC Sci Publ; 1996; (139):271-6. PubMed ID: 8923037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer prevention: chemoprevention vs dietary modifications.
    Goodman GE
    Prev Med; 1993 Sep; 22(5):689-92. PubMed ID: 8234208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.
    Lara PN; Higdon R; Lim N; Kwan K; Tanaka M; Lau DH; Wun T; Welborn J; Meyers FJ; Christensen S; O'Donnell R; Richman C; Scudder SA; Tuscano J; Gandara DR; Lam KS
    J Clin Oncol; 2001 Mar; 19(6):1728-33. PubMed ID: 11251003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How should we move the field of chemopreventive agent development forward in a productive manner?
    Meyskens FL; Szabo E
    Recent Results Cancer Res; 2005; 166():113-24. PubMed ID: 15648187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer chemoprevention with dietary phytochemicals.
    Surh YJ
    Nat Rev Cancer; 2003 Oct; 3(10):768-80. PubMed ID: 14570043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methodologic issues in the chemoprevention of breast cancer.
    Cuzick J
    Cancer Detect Prev; 1992; 16(1):81-5. PubMed ID: 1551142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer chemoprevention and cancer preventive vaccines--a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need.
    Herberman RB; Pearce HL; Lippman SM; Pyenson BS; Alberts DS
    Cancer Res; 2006 Dec; 66(24):11540-9. PubMed ID: 17158189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemoprevention: will it work?
    Mettlin C
    Int J Cancer; 1997; Suppl 10():18-21. PubMed ID: 9209015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention and early detection clinical trials: opportunities for primary care providers and their patients.
    Ford LG; Minasian LM; McCaskill-Stevens W; Pisano ED; Sullivan D; Smith RA
    CA Cancer J Clin; 2003; 53(2):82-101. PubMed ID: 12691266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoprevention of cancer--focusing on clinical trials.
    Kakizoe T
    Jpn J Clin Oncol; 2003 Sep; 33(9):421-42. PubMed ID: 14594936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemoprevention trials in the cervix: design, feasibility, and recruitment.
    Mitchell MF; Hittelman WN; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Hong WK
    J Cell Biochem Suppl; 1995; 23():104-12. PubMed ID: 8747384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chemoprevention of cancer. Prevention of cancer in groups with increased risk].
    Sanner T; Dybing E
    Tidsskr Nor Laegeforen; 1996 Aug; 116(19):2329-33. PubMed ID: 8804210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemoprevention research: implications for primary care practice.
    Denicoff AM; Padberg RM
    Lippincotts Prim Care Pract; 2000; 4(4):410-6. PubMed ID: 11261117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.